Skip to main content
    B

    Briacell Therapeutics Corp (BCTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.51
    +0.21 (+6.36%)

    Market Cap: $29.60M

    Last updated: Nov 17, 2026 at 4:37 PM ET

    Briacell Therapeutics Corp (BCTX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Briacell Therapeutics (BCTX) has a market cap of $29.60M and an enterprise value of $19.75M. It kept -13771.38% of revenue as net income over the last 12 months. Its share count is up 1843.48% from a year earlier.

    Total Valuation

    Enterprise value is 33.28% below the market cap, as cash exceeds debt.

    Market Cap$29.60M
    Enterprise Value$19.75M
    Latest price (Nov 17, 2026)$3.51

    Key Dates

    The next earnings report is expected on Dec 10, 2026, covering the quarter ending Oct 31, 2026.

    Next Earnings DateDec 10, 2026 (expected)
    Last Earnings DateOct 28, 2026
    Fiscal Year EndJuly

    Share Statistics

    The share count rose 158.73% in the quarter ended Apr 30, 2026.

    Shares Outstanding5.01M
    Shares Change (YoY)+1843.48%
    Shares Change (QoQ)+158.73%

    Valuation Ratios

    Forward P/S2.9x
    P/B Ratio1.1x
    P/TBV Ratio1.1x

    Price Statistics

    The stock is down 61.70% over 52 weeks and trades 5.39% below its 50-day average.

    Beta (1Y)1.57
    52-Week Change-61.70%
    1-Month Change+3.85%
    3-Month Change-11.36%
    5-Year Change-99.74%
    10-Year Change-99.96%
    Total Return (1Y)-61.70%
    Total Return (3Y CAGR)-82.47%
    Total Return (5Y CAGR)-70.31%
    Return vs SPY (1Y)-65.92%
    Max Drawdown (1Y)-78.32%
    Max Drawdown (3Y)-99.69%
    Sharpe Ratio (1Y)-0.63
    Correlation with SPY (1Y)0.17
    50-Day Average$3.71
    200-Day Average$3.75
    52-Week Range$2.60 to $13.09
    RSI (14 Days)49.6
    Average Volume (20 Days)65.43K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.76x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio2.76x
    Quick Ratio2.76x
    Debt / Equity0.00x

    Scores

    BCTX has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $225.34K over the last 12 months is up 893.96% from the 12 months before.

    Revenue$225.34K
    Revenue Growth (YoY)+893.96%
    Gross Profit-$63.57K
    Operating Income-$32.17M
    Pretax Income-$31.10M
    Net Income-$31.03M
    Reported EPS (TTM)-$9.16

    Trailing 12 months through Apr 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 69.55% of the $23.58M in total assets.

    Cash and Equivalents$9.85M
    Total Debt$0
    Net Cash$9.85M
    Net Cash Per Share$1.97
    Working Capital$14.06M
    Shareholder Equity$16.40M
    Book Value Per Share$3.27
    Tangible Book Value$16.23M
    Tangible Book Per Share$3.24
    Total Assets$23.58M
    Total Liabilities$8.02M

    Balance sheet as of Jul 31, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$28.71M
    FCF Per Share-$3.31
    Depreciation and Amortization$119.33K

    Trailing 12 months through Jul 31, 2026.

    Full cash flow statement

    Margins

    The operating margin is -14274.44%.

    Gross Margin-28.21%
    Operating Margin-14274.44%
    Pretax Margin-13803.30%
    Net Margin-13771.38%

    Stock Splits

    The last split was a 1-for-10 reverse split on Aug 25, 2025.

    Last Split DateAug 25, 2025
    Split TypeReverse split
    Split Ratio1:10

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About BCTX

    What is BCTX's market cap?

    Briacell Therapeutics has a market cap of $29.60M. Its enterprise value, which adds debt and subtracts cash, is $19.75M.

    How many shares of BCTX are outstanding?

    Briacell Therapeutics has 5.01M shares outstanding. The count is up 1843.48% from a year earlier.

    Does BCTX pay a dividend?

    No. Briacell Therapeutics does not pay a dividend.

    How much debt does BCTX have?

    Briacell Therapeutics has $0 of total debt and $9.85M of cash and equivalents, a net cash position of $9.85M.